Meeting
2018 Genitourinary Cancers Symposium
A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).
Authors
Chong-xian Pan
University of California Davis Comprehensive Cancer Center, Sacramento, CA
Chong-xian Pan , Primo Lara Jr., Christopher P. Evans , Mamta Parikh , Ralph de Vere White , Marc Dall'era , Chengfei Liu , Daniel Robles , Allen Gao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02935205
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr TPS394)
DOI
10.1200/JCO.2018.36.6_suppl.TPS394
Abstract #
TPS394
Poster Bd #
M14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
BMX inhibition and HSD3B1-driven resistance in prostate cancer in the Maverick trial.
First Author: Nima Sharifi
Poster
2019 Genitourinary Cancers Symposium
ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
First Author: Taavi Neklesa
Poster
2019 Genitourinary Cancers Symposium
Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue.
First Author: Adam Sharp
Poster
2018 Genitourinary Cancers Symposium
Niclosamide in combination with abiraterone and prednisone in men with castration-resistant prostate cancer (CRPC): initial results from a phase Ib/II trial.
First Author: Chong-xian Pan